var data={"title":"Foscarnet: Drug information","body":"<div id=\"topicContent\" class=\"utdArticleSection utdStyle\"><div id=\"drugTitle\">Foscarnet: Drug information</div><div id=\"lexiTitleImg\"></div><div class=\"clear\"></div><div id=\"lcoSearchClickUrl\"><a href=\"http://online.lexi.com/lco/action/api/find/globalid/6235?utd=1\" target=\"_blank\">Access Lexicomp Online here.</a></div><div id=\"drugCopy\">Copyright 1978-2018 Lexicomp, Inc. All rights reserved.</div><div id=\"topicText\">(For additional information <a href=\"topic.htm?path=foscarnet-patient-drug-information\" class=\"drug drug_patient\">see &quot;Foscarnet: Patient drug information&quot;</a> and <a href=\"topic.htm?path=foscarnet-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Foscarnet: Pediatric drug information&quot;</a>)<br></br>For abbreviations and symbols that may be used in Lexicomp (<a href=\"image.htm?imageKey=DRUG%2F57469\" class=\"graphic graphic_table\">show table</a>)<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F5708811\" class=\"block black-box-warn drugH1Div\"><span class=\"drugH1\">ALERT: US Boxed Warning</span>\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Renal impairment:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Renal impairment is the major toxicity of foscarnet. Frequent monitoring of serum creatinine, with dose adjustment for changes in renal function, and adequate hydration with administration of foscarnet is imperative.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Seizures:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Seizures, related to alterations in plasma minerals and electrolytes, have been associated with foscarnet treatment. Therefore, patients must be carefully monitored for such changes and their potential sequelae. Mineral and electrolyte supplementation may be required.</p></div>\r\n</div>\r\n\n    <div class=\"collapsible\">\n      <span class=\"collapsible-title\">Appropriate use:</span>\n      <div class=\"collapsible-wrap\">\n        <p style=\"text-indent:-2em;margin-left:2em;\">Foscarnet is indicated for use only in immunocompromised patients with cytomegalovirus (CMV) retinitis and mucocutaneous acyclovir-resistant herpes simplex virus (HSV) infections.</p></div>\r\n</div>\r\n</div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F14934198\" class=\"list ubnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: US</span>\n    <ul>\n      <li>Foscavir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174168\" class=\"list cbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: Canada</span>\n    <ul>\n      <li>Foscavir</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174208\" class=\"ex_sect_xr thclist drugH1Div drugBrandNames\"><span class=\"drugH1\">Pharmacologic Category</span>\n    <ul>\n      <li>\n        Antiviral Agent</li></ul></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174170\" class=\"block doa drugH1Div\"><span class=\"drugH1\">Dosing: Adult</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cytomegalovirus (CMV) retinitis:</b> IV: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Induction treatment:</i> 60 mg/kg/dose every 8 hours for 14 to 21 days <b>or</b> 90 mg/kg every 12 hours for 14 to 21 days</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">\n      <i>Maintenance therapy:</i> 90 to 120 mg/kg/day as a single daily infusion; due to lower toxicity, begin with 90 mg/kg once daily, may escalate to 120 mg/kg once daily if lower dose tolerated or for retinitis progression  </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV infection (preemptive therapy) after allogeneic stem cell transplantation (off-label use; second-line therapy):  </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;100 days post-transplant: Induction: 60 mg/kg every 12 hours for 7 to 14 days, followed by maintenance therapy: 90 mg/kg once daily if CMV is still detectable and declining, continue until indicator test is negative. Minimum total duration (induction and maintenance) is 2 weeks (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;100 days post-transplant: 60 mg/kg every 12 hours for 14 days, continue treatment with 90 mg/kg once daily for 7 to 14 days or until indicator test is negative (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV infection (prophylaxis) after allogeneic stem cell transplantation (off-label use; second-line therapy):  </b> IV: 60 mg/kg every 12 hours for 7 days, followed by 90 to 120 mg/kg once daily until day 100 after transplant (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV esophagitis or colitis in HIV-infected patients (alternative to preferred therapy) (off-label use):</b> IV: 60 mg/kg/dose every 8 hours or 90 mg/kg/dose every 12 hours for 21 to 42 days or until symptom resolution (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV neurological disease in HIV-infected patients (off-label use):</b> IV: 60 mg/kg/dose every 8 hours or 90 mg/kg/dose every 12 hours plus ganciclovir until symptoms improve followed by chronic maintenance suppression (secondary prophylaxis) (HHS [OI adult 2015])</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Herpes simplex infections (acyclovir-resistant): </b>Induction: IV: 40 mg/kg/dose every 8 to 12 hours for 14 to 21 days </p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50990633\" class=\"block dora drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">See tables. </p>\n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Induction Dosing of Foscarnet in Patients With Abnormal Renal Function</caption>\n      <col></col>\n      <col></col>\n      <col></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" valign=\"middle\" align=\"center\">\n            <p style=\"text-indent:0em;\"> CrCl (mL/min/kg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">HSV</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">HSV</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CMV</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CMV</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Equivalent to 40 mg/kg every 12 hours</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Equivalent to 40 mg/kg every 8 hours</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\"> Equivalent to 60 mg/kg every 8 hours</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Equivalent to 90 mg/kg every 12 hours</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;0.4 </p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;0.4-0.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.5-0.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 mg/kg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.6-0.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">25 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">80 mg/kg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.8-1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">20 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">35 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1-1.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">30 mg/kg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">45 mg/kg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70 mg/kg every 12 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 mg/kg every 12 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">40 mg/kg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 mg/kg every 8 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90 mg/kg every 12 hours</p></td></tr></tbody></table>\n    \n    <table border=\"1\" rules=\"all\" frame=\"border\">\n      <caption style=\"text-align:center;\">Maintenance Dosing of Foscarnet in Patients With Abnormal Renal Function</caption>\n      <col></col>\n      <col></col>\n      <col></col>\n      <thead valign=\"middle\">\n        <tr>\n          <th rowspan=\"2\" align=\"center\">\n            <p style=\"text-indent:0em;\">CrCl (mL/min/kg)</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CMV</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">CMV</p></th></tr>\n        <tr>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Equivalent to 90 mg/kg every 24 hours</p></th>\n          <th align=\"center\">\n            <p style=\"text-indent:0em;\">Equivalent to 120 mg/kg every 24 hours</p></th></tr></thead>\n      <tbody valign=\"top\">\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&lt;0.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">Not recommended</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&ge;0.4-0.5</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 48 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">65 mg/kg every 48 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.5-0.6</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">60 mg/kg every 48 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">80 mg/kg every 48 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.6-0.8</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">80 mg/kg every 48 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">105 mg/kg every 48 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;0.8-1</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">50 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">65 mg/kg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1-1.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">70 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90 mg/kg every 24 hours</p></td></tr>\n        <tr>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">&gt;1.4</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">90 mg/kg every 24 hours</p></td>\n          <td align=\"center\">\n            <p style=\"text-indent:0em;\">120 mg/kg every 24 hours</p></td></tr></tbody></table>\n    \n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Hemodialysis:</b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Foscarnet is highly removed by hemodialysis (up to ~38% in 2.5 hours HD with high-flux membrane) (Aweeka 1999)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Doses of 45 to 60 mg/kg/dose posthemodialysis (3 times/week) with the monitoring of weekly plasma concentrations to maintain peak plasma concentrations in the range of 500 to 800 micromolar  for the treatment of CMV infection have been recommended (Aweeka 1999; Jayasekara 1999; MacGregor 1991)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Peritoneal dialysis:</b> HSV infection (localized or disseminated):  IV: 60 mg/kg/dose every 48 to 72 hours; higher doses may be necessary for herpes encephalitis or herpes zoster infection (Jayasekara 1999)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F50987783\" class=\"block doha drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Adult)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F45612122\" class=\"block dop drugH1Div\"><span class=\"drugH1\">Dosing: Pediatric</span><p>(For additional information <a href=\"topic.htm?path=foscarnet-pediatric-drug-information\" class=\"drug drug_pediatric\">see &quot;Foscarnet: Pediatric drug information&quot;</a>)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cytomegalovirus (CMV) infection (preemptive therapy) after allogeneic stem cell transplantation (off-label use; second-line therapy):  </b> IV:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&lt;100 days post-transplant: Induction: 60 mg/kg every 12 hours for 7 to 14 days, followed by maintenance therapy: 90 mg/kg once daily if CMV is still detectable and declining, continue until indicator test is negative. Minimum total duration (induction and maintenance) is 2 weeks (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">&gt;100 days post-transplant: 60 mg/kg every 12 hours for 14 days, continue treatment with 90 mg/kg once daily for 7 to 14 days or until indicator test is negative (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV infection (prophylaxis) after allogeneic stem cell transplantation (off-label use; second-line therapy):  </b> IV: 60 mg/kg every 12 hours for 7 days, followed by 90 to 120 mg/kg once daily until day 100 after transplant (Tomblyn 2009)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV esophagitis or colitis in HIV-infected patients (alternative to preferred therapy) (off-label use):</b> Adolescents: Refer to adult dosing.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>CMV neurological disease in HIV-infected patients (off-label use):</b> Adolescents: Refer to adult dosing</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51130583\" class=\"block dorp drugH1Div\"><span class=\"drugH1\">Dosing: Renal Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no pediatric specific dosage adjustments available; based on experience in adult patients, dosage adjustment is suggested.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51130584\" class=\"block dohp drugH1Div\"><span class=\"drugH1\">Dosing: Hepatic Impairment (Pediatric)</span>\n    <p style=\"text-indent:0em;display:inline\">There are no dosage adjustments provided in the manufacturer&rsquo;s labeling.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174171\" class=\"block doe drugH1Div\"><span class=\"drugH1\">Dosing: Geriatric</span>\n    <p style=\"text-indent:0em;display:inline\">Refer to adult dosing.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174148\" class=\"block foc drugH1Div\"><span class=\"drugH1\">Dosage Forms</span>\n    <p style=\"text-indent:0em;text-align:justify;display:inline\">Excipient information presented when available (limited, particularly for generics); consult specific product labeling.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Solution, Intravenous, as sodium [preservative free]: </p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">Foscavir: 24 mg/mL (250 mL)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174134\" class=\"block geq drugH1Div\"><span class=\"drugH1\">Generic Equivalent Available (US)</span>\n    <p style=\"text-indent:0em;display:inline\">No</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174151\" class=\"block adm drugH1Div\"><span class=\"drugH1\">Administration</span>\n    <p style=\"text-indent:0em;display:inline\">IV: Foscarnet is administered by intravenous infusion, using an infusion pump, at a rate not exceeding 1 mg/kg/minute. Undiluted (24 mg/mL) solution can be administered without further dilution when using a central venous catheter for infusion. For peripheral vein administration, the solution <b>must</b> be diluted to a final concentration <b>not to exceed</b> 12 mg/mL. The manufacturer recommends 750 to 1000 mL of NS or D<sub>5</sub>W be administered prior to first infusion to establish diuresis. With subsequent infusions of 90 to 120 mg/kg, this volume would be repeated. If the dose were 40 to 60 mg/kg, then the volume could be reduced to 500 mL. After the first dose, the hydration fluid should be administered concurrently with foscarnet.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174150\" class=\"block use drugH1Div\"><span class=\"drugH1\">Use</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Cytomegalovirus retinitis:</b> Treatment of cytomegalovirus (CMV) retinitis in persons with AIDS</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\"> <b>Herpes simplex virus:</b> Treatment of acyclovir-resistant mucocutaneous herpes simplex virus (HSV) infections in immunocompromised persons (eg, with advanced AIDS)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F25725560\" class=\"block off-label drugH1Div\"><span class=\"drugH1\">Use: Off-Label</span>\n    <p>CMV esophagitis or colitis treatment in HIV-infected patients (adolescents and adults); CMV infection (preemptive therapy) after allogeneic stem cell transplantation; CMV infection (prophylaxis) after allogeneic stem cell transplantation; CMV neurological disease in HIV-infected patients (adolescents and adults)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174141\" class=\"block adr drugH1Div\"><span class=\"drugH1\">Adverse Reactions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&gt;10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Headache (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hypokalemia (16% to 48%), hypocalcemia (15% to 30%), hypomagnesemia (15% to 30%), hypophosphatemia (8% to 26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Nausea (47%), diarrhea (30%), vomiting (26%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Anemia (33%), granulocytopenia (17%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Renal insufficiency (27%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Miscellaneous: Fever (65%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">1% to 10%:</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Cardiovascular: Chest pain (1% to 5%; including transient chest pain as part of infusion reactions), edema (1% to 5%), facial edema (1% to 5%), first degree atrioventricular block (1% to 5%), flushing (1% to 5%), hypertension (1% to 5%), hypotension (1% to 5%), palpitations (1% to 5%), sinus tachycardia (1% to 5%), ST segment changes on ECG (1% to 5%), thrombosis (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Central nervous system: Seizure (10%), anxiety (&ge;5%), confusion (&ge;5%), depression (&ge;5%), dizziness (&ge;5%), fatigue (&ge;5%), hypoesthesia (&ge;5%), malaise (&ge;5%), neuropathy (&ge;5%), pain (&ge;5%), paresthesia (&ge;5%), rigors (&ge;5%), abnormal electroencephalogram (1% to 5%), aggressive behavior (1% to 5%), agitation (1% to 5%), amnesia (1% to 5%), aphasia (1% to 5%), ataxia (1% to 5%), cerebrovascular disease (1% to 5%), dementia (1% to 5%), hallucination (1% to 5%), insomnia (1% to 5%), meningitis (1% to 5%), nervousness (1% to 5%), sensory disturbance (1% to 5%), somnolence (1% to 5%), stupor (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Dermatologic: Diaphoresis (&ge;5%), skin rash (&ge;5%), dermal ulcer (1% to 5%), erythematous rash (1% to 5%), maculopapular rash (1% to 5%), pruritus (1% to 5%), seborrhea (1% to 5%), skin discoloration (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Endocrine &amp; metabolic: Hyperphosphatemia (6%), electrolyte disturbance (&ge;5%), abnormal albumin-Globulin ratio (1% to 5%), acidosis (1% to 5%), albuminuria (1% to 5%), cachexia (1% to 5%), hyponatremia (1% to 5%), increased lactate dehydrogenase (1% to 5%), increased thirst (1% to 5%), weight loss (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Gastrointestinal: Abdominal pain (&ge;5%), anorexia (&ge;5%), aphthous stomatitis (1% to 5%), cachexia (1% to 5%), constipation (1% to 5%), dysgeusia (1% to 5%), dyspepsia (1% to 5%), dysphagia (1% to 5%), flatulence (1% to 5%), melena (1% to 5%), pancreatitis (1% to 5%), xerostomia (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Genitourinary: Nephrotoxicity (8%), dysuria (1% to 5%), nocturia (1% to 5%), urinary retention (1% to 5%), urinary tract infection (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hematologic &amp; oncologic: Bone marrow suppression (10%), leukopenia (&ge;5%), mineral abnormalities (&ge;5%), neutropenia (&ge;5%), abnormal white cell differential (1% to 5%), altered platelet function (1% to 5%), lymphadenopathy (1% to 5%), pseudolymphoma (1% to 5%), rectal hemorrhage (1% to 5%), sarcoma (1% to 5%), thrombocytopenia (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Hepatic: Abnormal hepatic function tests (1% to 5%), increased lactate dehydrogenase (1% to 5%), increased serum alkaline phosphatase (1% to 5%), increased serum ALT (1% to 5%), increased serum AST (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Infection: Infection (&ge;5%), sepsis (&ge;5%), abscess, bacterial infection (1% to 5%), fungal infection (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Local: Inflammation at injection site (1% to 5%), pain at injection site (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Neuromuscular &amp; skeletal: Muscle spasm (&ge;5%), neuropathy (peripheral; &ge;5%), weakness (&ge;5%), arthralgia (1% to 5%), back pain (1% to 5%), leg cramps (1% to 5%), myalgia (1% to 5%), tremor (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Ophthalmic: Visual disturbance (&ge;5%), conjunctivitis (1% to 5%), eye pain (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Renal: Decreased creatinine clearance (&ge;5%), increased serum creatinine (&ge;5%), acute renal failure (1% to 5%), increased blood urea nitrogen (1% to 5%), polyuria (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">Respiratory: Cough (&ge;5%), dyspnea (&ge;5%), bronchospasm (1% to 5%), flu-like symptoms (1% to 5%), hemoptysis (1% to 5%), pharyngitis (1% to 5%), pneumonia (1% to 5%), pneumothorax (1% to 5%), pulmonary infiltrates (1% to 5%), respiratory failure (1% to 5%), respiratory insufficiency (1% to 5%), rhinitis (1% to 5%), sinusitis (1% to 5%), stridor (1% to 5%)</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">&lt;1%, postmarketing, and/or case reports: Coma, dehydration, diabetes insipidus (usually nephrogenic), erythema multiforme, esophageal ulcer, extravasation, Fanconi syndrome, gastrointestinal hemorrhage, glomerulonephritis, hematuria, hypercalcemia, hypersensitivity reaction (including anaphylactic shock, angioedema, urticaria), hypoproteinemia, increased amylase, increased creatine phosphokinase, increased gamma-glutamyl transferase, increased serum lipase, local irritation (genitals), localized edema, myasthenia, myopathy, myositis, nephrolithiasis, nephrotic syndrome, pancytopenia, penile ulceration, prolonged Q-T interval on ECG, proteinuria, renal disease (crystal-induced), renal tubular acidosis, renal tubular necrosis, rhabdomyolysis, SIADH, status epilepticus, Stevens-Johnson syndrome, torsades de pointes, toxic epidermal necrolysis, vaginal ulcer, ventricular arrhythmia</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174154\" class=\"block coi drugH1Div\"><span class=\"drugH1\">Contraindications</span>\n    <p style=\"text-indent:0em;display:inline\">Clinically significant hypersensitivity to foscarnet or any component of the formulation.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174138\" class=\"block war drugH1Div\"><span class=\"drugH1\">Warnings/Precautions</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concerns related to adverse effects:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Dental effects: Foscarnet is deposited in teeth and bone of young, growing animals; it has adversely affected tooth enamel development in rats.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Electrolyte imbalance: Imbalance of serum electrolytes or minerals occurs in at least 15% of patients (hypocalcemia, low ionized calcium, hyper/hypophosphatemia, hypomagnesemia, or hypokalemia); reducing infusion rate may decrease/prevent symptoms. Patients with low ionized calcium may experience perioral tingling, numbness, paresthesias, tetany, and seizures. Correct electrolytes before initiating therapy; use caution in patients who have any underlying electrolyte imbalances, those with neurologic or cardiac abnormalities, and those receiving medications that are influenced by calcium levels. Use caution when administering other medications that cause electrolyte imbalances. Patients who experience signs or symptoms of an electrolyte imbalance should be assessed immediately.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hematologic effects: May cause anemia and granulocytopenia.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Hypersensitivity: Serious hypersensitivity reactions, including anaphylactic shock and angioedema, have been reported. Discontinue immediately and institute appropriate medical therapy if an acute reaction occurs.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Renal impairment: <b>[US Boxed Warning]: Renal impairment occurs to some degree in the majority of patients treated with foscarnet;</b> renal impairment may occur at any time (though typically during second week of induction therapy) and is usually reversible within 1 week following dose adjustment or discontinuation of therapy, however, several patients have died with renal failure within 4 weeks of stopping foscarnet; therefore, renal function should be closely monitored during both induction and maintenance therapy. To reduce the risk of nephrotoxicity and the potential to administer a relative overdose, always calculate the CrCl even if serum creatinine is within the normal range. Dosage adjustments are recommended for renal dysfunction; safety and efficacy in patients with a baseline S<sub>cr</sub> &gt;2.8 mg/dL or CrCl &lt;50 mL/minute are limited. Use in patients with CrCl &lt;0.4 mL/kg/minute is not recommended. Adequate hydration may reduce the risk of nephrotoxicity; the manufacturer makes specific recommendations regarding this (see Administration).</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; QT prolongation: QT prolongation, including torsades de pointes, has been reported; some reports occurred in patients with confounding risk factors (eg, underlying cardiac disease, electrolyte abnormalities, concomitant medications). Use with caution in patients with a history of QT prolongation or those at increased risk for QT prolongation.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Seizures: <b>[US Boxed Warning]: Seizures related to plasma electrolyte/mineral imbalance may occur;</b> incidence has been reported in up to 10% of HIV patients. Risk factors for seizures include impaired baseline renal function, low total serum calcium, and underlying CNS condition. Some patients who have experienced seizures have been able to continue or resume foscarnet treatment after their mineral or electrolyte abnormality has been corrected, their underlying disease state treated, or their dose decreased.</p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Vascular irritant: Administer only into vein with adequate blood flow to prevent tissue irritation/ulceration. Genital vascular tissue damage has been reported; adequate hydration recommended.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Disease related concerns:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Heart failure: Due to sodium content, use with caution in patients with heart failure.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Concurrent drug therapy issues:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Drug-drug interactions: Potentially significant interactions exist, requiring dose or frequency adjustment, additional monitoring, and/or selection of alternative therapy. Consult drug interactions database for more detailed information.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">\n      <b>\n        <i>Other warnings/precautions:</i></b></p>\n    <p style=\"text-indent:-2em;margin-left:4em;\">&bull; Appropriate use: <b>[US Boxed Warning]: Indicated only for immunocompromised patients with CMV retinitis and mucocutaneous acyclovir-resistant HSV infection.</b></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F13299364\" class=\"block cyt drugH1Div\"><span class=\"drugH1\">Metabolism/Transport Effects</span>\n    <p style=\"text-indent:0em;display:inline\">None known.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174143\" class=\"block dri drugH1Div\"><span class=\"drugH1\">Drug Interactions</span>\n    <br/><br/><div id=\"lexiInteractAddInfo\" class=\"lexi\">(For additional information: <a href=\"https://www.uptodate.com/drug-interactions/?search=&amp;topicId=8476&amp;source=responsive_topic\" class=\"dip\" target=\"_blank\">Launch drug interactions program</a>)</div><div id=\"lexiInteractImgB\" class=\"lexi\"><img src=\"/images/lexiComp/Lexicomp_2012_71x17.gif\" width=\"71\" height=\"17\" border=\"0\"/></div><div class=\"clear\"></div><p style=\"text-indent:-2em;margin-left:2em;\">Acyclovir-Valacyclovir: Foscarnet may enhance the nephrotoxic effect of Acyclovir-Valacyclovir. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Aminoglycosides: Foscarnet may enhance the nephrotoxic effect of Aminoglycosides. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Amphotericin B: Foscarnet may enhance the nephrotoxic effect of Amphotericin B. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">CycloSPORINE (Systemic): Foscarnet may enhance the nephrotoxic effect of CycloSPORINE (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Loop Diuretics: May increase the serum concentration of Foscarnet.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Methotrexate: Foscarnet may enhance the nephrotoxic effect of Methotrexate. <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">MiFEPRIStone: May enhance the QTc-prolonging effect of QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying). Management: Though the drugs listed here have uncertain QT-prolonging effects, they all have some possible association with QT prolongation and should generally be avoided when possible.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Pentamidine (Systemic): May enhance the adverse/toxic effect of Foscarnet. The specific toxicities may include hypocalcemia, renal failure, and QT-prolongation. Management: Consider alternatives to this combination when possible.  If this combination must be used, monitor patients more closely for hypocalcemia, renal dysfunction, and QT interval prolongation.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Highest Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Highest Risk).  Management: Avoid such combinations when possible.  Use should be accompanied by close monitoring for evidence of QT prolongation or other alterations of cardiac rhythm.<i> Risk D: Consider therapy modification</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">QTc-Prolonging Agents (Moderate Risk): QTc-Prolonging Agents (Indeterminate Risk and Risk Modifying) may enhance the QTc-prolonging effect of QTc-Prolonging Agents (Moderate Risk). <i> Risk C: Monitor therapy</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Tacrolimus (Systemic): Foscarnet may enhance the nephrotoxic effect of Tacrolimus (Systemic). <i> Risk X: Avoid combination</i></p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Talimogene Laherparepvec: Antiherpetic Antivirals may diminish the therapeutic effect of Talimogene Laherparepvec. <i> Risk C: Monitor therapy</i></p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3051197\" class=\"block pri drugH1Div\"><span class=\"drugH1\">Pregnancy Implications</span>\n    <p style=\"text-indent:0em;display:inline\">Information related to use in pregnancy is limited (Alvarez-McLeod 1999). Monitoring of amniotic fluid volumes by ultrasound is recommended weekly after 20 weeks of gestation to detect oligohydramnios (HHS [OI adult 2015]).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174157\" class=\"block brc drugH1Div\"><span class=\"drugH1\">Breast-Feeding Considerations</span>\n    <p style=\"text-indent:0em;\">It is not known if foscarnet is present in breast milk.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Due to the potential for serious adverse reactions in the breastfeeding infant, the manufacturer recommends a decision be made whether to discontinue breastfeeding or to discontinue the drug, taking into account the importance of treatment to the mother.</p>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Females with HIV infection should completely avoid breastfeeding to decrease the potential transmission of HIV (HHS [perinatal] 2017).</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F26841942\" class=\"block dic drugH1Div\"><span class=\"drugH1\">Dietary Considerations</span>\n    <p style=\"text-indent:0em;display:inline\">Some products may contain sodium.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F3051199\" class=\"block mop drugH1Div\"><span class=\"drugH1\">Monitoring Parameters</span>\n    <p style=\"text-indent:0em;display:inline\">24-hour creatinine clearance, ECG, and electrolytes at baseline and periodically thereafter (when clinically appropriate). During induction therapy: Obtain complete blood counts, and electrolytes (including serum creatinine, calcium, magnesium, potassium, and phosphorus) twice weekly and then one weekly during maintenance therapy. More frequent monitoring may be required in some patients. Check hydration status before and after infusion.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174137\" class=\"block pha drugH1Div\"><span class=\"drugH1\">Mechanism of Action</span>\n    <p style=\"text-indent:0em;display:inline\">Pyrophosphate analogue which acts as a noncompetitive inhibitor of many viral RNA and DNA polymerases as well as HIV reverse transcriptase. Similar to ganciclovir, foscarnet is a virostatic agent. Foscarnet does not require activation by thymidine kinase.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F174153\" class=\"block phk drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Distribution: V<sub>d</sub>: ~0.5 L/kg; up to 28% of cumulative IV dose may be deposited in bone</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Protein binding: 14% to 17%</p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Metabolism: Biotransformation does not occur </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Half-life elimination: Elimination: ~3 to 4 hours; terminal: ~88 hours (due to bone deposition) </p>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">Excretion: Urine (&le;28% as unchanged drug)</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F51192661\" class=\"block phksp drugH1Div\"><span class=\"drugH1\">Pharmacodynamics/Kinetics: Additional Considerations</span>\n    <p style=\"text-indent:-2em;margin-left:2em;\">Renal function impairment: CrCl of 50 to 80 mL/minute has a clearance of about 1.33 mL/minute/kg and a plasma half-life of about 3.35 hours. CrCl of 25 to 49 mL/minute has a clearance of about 0.46 mL/minute/kg and a plasma half-life of about 13 hours. CrCl of 10 to 24 mL/minute has a clearance of 0.43 mL/minute/kg and plasma half-life about 25.3 hours.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F16323160\" class=\"block fee drugH1Div\"><span class=\"drugH1\">Pricing: US</span>\n    <p style=\"text-indent:-2em;margin-left:2em;text-align:justify;\">\n      <b>Solution</b> (Foscavir Intravenous)</p>\n    <p style=\"text-indent:-2em;margin-left:4em;text-align:justify;\">6000 mg/250 mL (250 mL): $558.80</p>\n    <p style=\"text-indent:0em;\">\n      <b>Disclaimer: </b>A representative AWP (Average Wholesale Price) price or price range is provided as reference price only. A range is provided when more than one manufacturer's AWP price is available and uses the low and high price reported by the manufacturers to determine the range. The pricing data should be used for benchmarking purposes only, and as such should not be used alone to set or adjudicate any prices for reimbursement or purchasing functions or considered to be an exact price for a single product and/or manufacturer.  Medi-Span expressly disclaims all warranties of any kind or nature, whether express or implied, and assumes no liability with respect to accuracy of price or price range data published in its solutions.  In no event shall Medi-Span be liable for special, indirect, incidental, or consequential damages arising from use of price or price range data.  Pricing data is updated monthly.</p></div>\r\n<div xmlns=\"http://www.w3.org/1999/xhtml\" id=\"F6038643\" class=\"list fbnlist drugH1Div drugBrandNames\"><span class=\"drugH1\">Brand Names: International</span>\n    <ul>\n      <li>Carnet (CN);</li>\n      <li>Foscarnet Elea (AR);</li>\n      <li>Foscarnet Filaxis (AR);</li>\n      <li>Foscarnet Richmond (AR);</li>\n      <li>Foscavir (AR, AT, AU, BE, CH, CZ, DE, ES, FI, FR, GB, GR, HN, HU, IL, IT, JP, KR, LU, NL, NZ, PT, SE, SG);</li>\n      <li>Fu Shi Ling (CN);</li>\n      <li>Terap (AR);</li>\n      <li>Triapten (PL)</li></ul></div>\r\n</div><div id=\"topicAgreement\">Use of UpToDate is subject to the <a href=\"https://www.uptodate.com/legal/license\" class=\"licenseLink\" id=\"sla_in_page\">Subscription and License Agreement</a>.</div><div id=\"references\" class=\"headingAnchor\"><h1>REFERENCES</h1><ol id=\"reference\">\r\n<li>\r\n<div class=\"reference\">\n    Alvarez-McLeod A, Havlik J, Drew KE. Foscarnet treatment of genital infection due to acyclovir-resistant herpes simplex virus type 2 in a pregnant patient with AIDS: case report. <i>Clin Infect Dis</i>. 1999;29(4):937-938.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/10589917/pubmed\" target=\"_blank\" id=\"10589917\">10589917</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Aweeka FT, Jacobson MA, Martin-Munley S, et al, &ldquo;Effect of Renal Disease and Hemodialysis on Foscarnet Pharmacokinetics and Dosing Recommendations,&rdquo; <i>J Acquir Immune Def Syndr Hum Retrovirol</i>, 1999, 20(4):350-7.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/10096579/pubmed\" target=\"_blank\" id=\"10096579\">10096579</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Butler KM, DeSmet MD, Husson RN, et al, &ldquo;Treatment of Aggressive Cytomegalovirus Retinitis With Ganciclovir in Combination With Foscarnet in a Child Infected With Human Immunodeficiency Virus,&rdquo; <i>J Pediatr</i>, 1992, 120(3):483-6.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/1311378/pubmed\" target=\"_blank\" id=\"1311378\">1311378</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Calligaro KD, Stern J, and DeLaurentis DA, &ldquo;Foscarnet: A Possible Cause of Ulnar Artery Thrombosis in a Patient With AIDS,&rdquo; <i>J Vasc Surg</i>, 1994, 20(6):1007-8.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/7990178/pubmed\" target=\"_blank\" id=\"7990178\">7990178</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chilukuri S and Rosen T, &quot;Management of Acycovir-Resistant Herpes Simplex Virus,&quot; <i>Dermatol Clin</i>, 2003, 21(2):311-20.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/12757254/pubmed\" target=\"_blank\" id=\"12757254\">12757254</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Chrisp P and Clissold SP, &ldquo;Foscarnet. A Review of Its Antiviral Activity, Pharmacokinetic Properties and Therapeutic Use in Immunocompromised Patients With Cytomegalovirus Retinitis,&rdquo; <i>Drugs</i>, 1991, 41(1):104-29.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/1706982/pubmed\" target=\"_blank\" id=\"1706982\">1706982</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Deray G, Martinez F, Katlama C, et al, &ldquo;Foscarnet Nephrotoxicity: Mechanism, Incidence and Prevention,&rdquo; <i>Am J Nephrol</i>, 1989, 9:316-21.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/2554731/pubmed\" target=\"_blank\" id=\"2554731\">2554731</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    &quot;Drugs for Non-HIV Viral Infections,&quot; <i>Med Lett Drugs Ther</i>, 1994, 36(919):27.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/8127252/pubmed\" target=\"_blank\" id=\"8127252\">8127252</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Foscavir (foscarnet) [prescribing information]. Lake Forest, IL: Hospira; February 2017.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jacobson MA, &ldquo;Review of the Toxicities of Foscarnet,&rdquo; <i>J Acquir Immune Defic Syndr</i>, 1992, 5(Suppl 1):11-7.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jayasekara D, Aweeka FT, Rodriguez R, et al. Antiviral therapy for HIV patients with renal insufficiency. <i>J Acquir Immune Defic Syndr</i>. 1999;21:384-395.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/10458619/pubmed\" target=\"_blank\" id=\"10458619\">10458619</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Jayaweera DT, &ldquo;Minimizing the Dosage-Limiting Toxicities of Foscarnet Induction Therapy,&rdquo; <i>Drug Saf</i>, 1997, 16(4):258-66.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/9113493/pubmed\" target=\"_blank\" id=\"9113493\">9113493</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Keating MR, &ldquo;Antiviral Agents,&rdquo; <i>Mayo Clin Proc</i>, 1992, 67(2):160-78.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/1347578/pubmed\" target=\"_blank\" id=\"1347578\">1347578</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    MacGregor RR, Graziani AL, Weiss R, et al. Successful foscarnet therapy for cytomegalovirus retinitis in an AIDS patient undergoing hemodialysis: rationale for empiric dosing and plasma level monitoring. <i>J Infect Dis</i>. 1991;164:785-787.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/1654363/pubmed\" target=\"_blank\" id=\"1654363\">1654363</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Morales JM, Munoz MA, Fernandez Zatarain G, et al, &ldquo;Reversible Acute Renal Failure Caused by the Combined Use of Foscarnet and Cyclosporin in Organ Transplanted Patients,&rdquo; <i>Nephrol Dial Transplant</i>, 1995, 10(6):882-3.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/7566623/pubmed\" target=\"_blank\" id=\"7566623\">7566623</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    Polis MA, &ldquo;Foscarnet and Ganciclovir in the Treatment of Cytomegalovirus Retinitis,&rdquo; <i>J Acquir Immune Defic Syndr</i>, 1992, 5(Suppl 1):3-10.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"11830461\"></a>Reusser P, Einsele H, Lee J, et al; Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Randomized multicenter trial of foscarnet versus ganciclovir for preemptive therapy of cytomegalovirus infection after allogeneic stem cell transplantation. <i>Blood</i>. 2002, 15;99(4):1159-1164.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/11830461/pubmed\" target=\"_blank\" id=\"11830461\">11830461</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    \n      <a name=\"19747629\"></a>Tomblyn M, Chiller T, Einsele H, et al; Center for International Blood and Marrow Research; National Marrow Donor program; European Blood and Marrow Transplant Group; American Society of Blood and Marrow Transplantation; Canadian Blood and Marrow Transplant Group; Infectious Diseases Society of America; Society for Healthcare Epidemiology of America; Association of Medical Microbiology and Infectious Disease Canada; Centers for Disease Control and Prevention. Guidelines for preventing infectious complications among hematopoietic cell transplantation recipients: a global perspective [published correction appears in <i>Biol Blood Marrow Transplant</i>. 2010;16(2):294]. <i>Biol Blood Marrow Transplant</i>. 2009;15(10):1143-1238.<span class=\"pubmed-id\"> [PubMed <a href=\"https://www.uptodate.com/contents/foscarnet-drug-information/abstract-text/19747629/pubmed\" target=\"_blank\" id=\"19747629\">19747629</a>]</span></div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Opportunistic Infections in HIV-Infected Adults and Adolescents. Guidelines for the prevention and treatment of opportunistic infections in HIV-infected adults and adolescents: recommendations from the Centers for Disease Control and Prevention, the National Institutes of Health, and the HIV Medicine Association of the Infectious Diseases Society of America. <a href=\"http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf\" target=\"_blank\">http://aidsinfo.nih.gov/contentfiles/lvguidelines/adult_oi.pdf</a>. Updated November 2015. Accessed January 10, 2018.</div>\r\n</li>\r\n<li>\r\n<div class=\"reference\">\n    US Department of Health and Human Services Panel on Treatment of Pregnant Women With HIV Infection and Prevention of Perinatal Transmission. Recommendations for the use of antiretroviral drugs in pregnant women with HIV infection and interventions to reduce perinatal HIV transmission in the United States. <a href=\"https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0\" target=\"_blank\">https://aidsinfo.nih.gov/guidelines/html/3/perinatal/0</a>. Updated November 14, 2017. Accessed December 21, 2017.</div>\r\n</li></ol></div><div id=\"topicVersionRevision\">Topic 8476 Version 142.0</div></div>","outline":"<div id=\"outlineSections\"><h2>Topic Outline</h2><ul><li class=\"plainItem\"><a sectionName=\"ALERT: US Boxed Warning\" href=\"#F5708811\" class=\"outlineLink\">ALERT: US Boxed Warning</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: US\" href=\"#F14934198\" class=\"outlineLink\">Brand Names: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: Canada\" href=\"#F174168\" class=\"outlineLink\">Brand Names: Canada</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacologic Category\" href=\"#F174208\" class=\"outlineLink\">Pharmacologic Category</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Adult\" href=\"#F174170\" class=\"outlineLink\">Dosing: Adult</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Adult)\" href=\"#F50990633\" class=\"outlineLink\">Dosing: Renal Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Adult)\" href=\"#F50987783\" class=\"outlineLink\">Dosing: Hepatic Impairment (Adult)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Pediatric\" href=\"#F45612122\" class=\"outlineLink\">Dosing: Pediatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Renal Impairment (Pediatric)\" href=\"#F51130583\" class=\"outlineLink\">Dosing: Renal Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Hepatic Impairment (Pediatric)\" href=\"#F51130584\" class=\"outlineLink\">Dosing: Hepatic Impairment (Pediatric)</a></li><li class=\"plainItem\"><a sectionName=\"Dosing: Geriatric\" href=\"#F174171\" class=\"outlineLink\">Dosing: Geriatric</a></li><li class=\"plainItem\"><a sectionName=\"Dosage Forms\" href=\"#F174148\" class=\"outlineLink\">Dosage Forms</a></li><li class=\"plainItem\"><a sectionName=\"Generic Equivalent Available (US)\" href=\"#F174134\" class=\"outlineLink\">Generic Equivalent Available (US)</a></li><li class=\"plainItem\"><a sectionName=\"Administration\" href=\"#F174151\" class=\"outlineLink\">Administration</a></li><li class=\"plainItem\"><a sectionName=\"Use\" href=\"#F174150\" class=\"outlineLink\">Use</a></li><li class=\"plainItem\"><a sectionName=\"Use: Off-Label\" href=\"#F25725560\" class=\"outlineLink\">Use: Off-Label</a></li><li class=\"plainItem\"><a sectionName=\"Adverse Reactions\" href=\"#F174141\" class=\"outlineLink\">Adverse Reactions</a></li><li class=\"plainItem\"><a sectionName=\"Contraindications\" href=\"#F174154\" class=\"outlineLink\">Contraindications</a></li><li class=\"plainItem\"><a sectionName=\"Warnings/Precautions\" href=\"#F174138\" class=\"outlineLink\">Warnings/Precautions</a></li><li class=\"plainItem\"><a sectionName=\"Metabolism/Transport Effects\" href=\"#F13299364\" class=\"outlineLink\">Metabolism/Transport Effects</a></li><li class=\"plainItem\"><a sectionName=\"Drug Interactions\" href=\"#F174143\" class=\"outlineLink\">Drug Interactions</a></li><li class=\"plainItem\"><a sectionName=\"Pregnancy Implications\" href=\"#F3051197\" class=\"outlineLink\">Pregnancy Implications</a></li><li class=\"plainItem\"><a sectionName=\"Breast-Feeding Considerations\" href=\"#F174157\" class=\"outlineLink\">Breast-Feeding Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Dietary Considerations\" href=\"#F26841942\" class=\"outlineLink\">Dietary Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Monitoring Parameters\" href=\"#F3051199\" class=\"outlineLink\">Monitoring Parameters</a></li><li class=\"plainItem\"><a sectionName=\"Mechanism of Action\" href=\"#F174137\" class=\"outlineLink\">Mechanism of Action</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics\" href=\"#F174153\" class=\"outlineLink\">Pharmacodynamics/Kinetics</a></li><li class=\"plainItem\"><a sectionName=\"Pharmacodynamics/Kinetics: Additional Considerations\" href=\"#F51192661\" class=\"outlineLink\">Pharmacodynamics/Kinetics: Additional Considerations</a></li><li class=\"plainItem\"><a sectionName=\"Pricing: US\" href=\"#F16323160\" class=\"outlineLink\">Pricing: US</a></li><li class=\"plainItem\"><a sectionName=\"Brand Names: International\" href=\"#F6038643\" class=\"outlineLink\">Brand Names: International</a></li><li class=\"plainItem\"><a href=\"#references\">REFERENCES</a></li></ul></div><div><h2>GRAPHICS <a href=\"#\" id=\"viewAllGraphicsLink\">View All</a></h2><div id=\"outlineGraphics\"><ul><li><div id=\"DRUG_GEN/8476|TAB\" class=\"openRelatedGraphics\"><a href=\"#\" title=\"TABLES\">TABLES</a></div><ul><li><a href=\"image.htm?imageKey=DRUG/57469\" class=\"graphic graphic_table\">- Lexicomp clinical abbreviations</a></li></ul></li></ul></div></div><div><h2>RELATED TOPICS</h2><div id=\"outlineTopics\"><ul><li><a href=\"topic.htm?path=foscarnet-patient-drug-information\" class=\"drug drug_patient\">Foscarnet: Patient drug information</a></li><li><a href=\"topic.htm?path=foscarnet-pediatric-drug-information\" class=\"drug drug_pediatric\">Foscarnet: Pediatric drug information</a></li></ul></div></div>","javascript":null}